Royalty Monetization

While royalty monetization is appealing to life science company investors due to its flexibility in structuring agreements to achieve performance goals for bringing complex therapies to market, there are numerous tax considerations involved in these agreements.

Our royalty monetization team specializes in representing clients in the buying and selling of, or financing secured by, interests in royalty and synthetic streams related to life sciences and pharmaceutical products. We possess extensive experience in transactions that involve contingent considerations, such as royalty payments and milestone payments.

Our skilled lawyers collaborate with investors on all tax-related issues arising from these transactions, structuring them in a tax-efficient manner and conducting technical and legal due diligence on the underlying intellectual property to reduce potential market risk. We leverage support from related practices within the firm, including corporate mergers and acquisitions (M&A), investment management, intellectual property, regulatory, and healthcare and life sciences, as necessary to manage all facets of a deal.